Sensorion (BST:RFM) - Stock Price, News & Analysis

RFM Stock Overview

A biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.

RFM fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 44.91% per year

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 22.3% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Sensorion SA Competitors

Heidelberg Pharma

XTRA:HPHA

€121.2m

Formycon

XTRA:FYB

€870.5m

Biotest

XTRA:BIO3

€1.4b

2invest

XTRA:2INV

€59.2m

Price History & Performance

Summary of all time highs, changes and price drops for Sensorion
Historical stock prices
Current Share Price	€0.73
52 Week High	€0.80
52 Week Low	€0.66
Beta	1.36
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-61.11%
5 Year Change	-52.21%
Change since IPO	-71.84%

Recent updates

Shareholder Returns

	RFM	DE Biotechs	DE Market
7D	0%	-0.4%	-1.8%
1Y	n/a	-14.9%	13.2%

Return vs Industry: Insufficient data to determine how RFM performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how RFM performed against the German Market.

Price Volatility

Is RFM's price volatile compared to industry and market?
RFM volatility
RFM Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: RFM has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine RFM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	57	Nawal Ouzren	www.sensorion.com

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation.

Sensorion SA Fundamentals Summary

How do Sensorion's earnings and revenue compare to its market cap?
RFM fundamental statistics
Market cap	€202.25m
Earnings (TTM)	-€22.06m
Revenue (TTM)	€5.57m

36.3x

P/S Ratio

-9.2x

P/E Ratio

Is RFM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RFM income statement (TTM)
Revenue	€5.57m
Cost of Revenue	€0
Gross Profit	€5.57m
Other Expenses	€27.63m
Earnings	-€22.06m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.074
Gross Margin	100.00%
Net Profit Margin	-396.45%
Debt/Equity Ratio	6.0%

How did RFM perform over the long term?

See historical performance and comparison

RFM Stock Overview

Rewards

Risk Analysis

Sensorion SA Competitors

XTRA:HPHA

€121.2m

XTRA:FYB

€870.5m

XTRA:BIO3

€1.4b

XTRA:2INV

€59.2m

Price History & Performance

Recent News & Updates

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Recent updates

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation

Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

Sensorion SA announced that it expects to receive €4.999999 million in funding from Sonova Holding AG

Sensorion and Novasep Announce Signature of A Gene Therapy Product Development and Manufacturing Agreement

Sensorion SA has completed a Follow-on Equity Offering in the amount of €31.0012 million.